High-purity, plasma-derived, pasteurized Factor VIII concentrates in the treatment of patients with haemophilia A: update of a long-term pharmacovigilance study

被引：0
|
作者：
Klamroth, Robert [1 ]
Holzhauer, Susanne [2 ]
Heller, Christine [3 ]
Sommerer, Patrick [4 ]
Kurnik, Karin [5 ]
机构：
[1] Vivantes Klinikum Friedrichshain, Berlin, Germany
[2] Univ Hosp Charite, Berlin, Germany
[3] Goethe Univ Frankfurt, Comprehens Care Ctr Thrombosis & Haemostasis, D-60054 Frankfurt, Germany
[4] CSL Behring GmbH, Marburg, Germany
[5] Univ Hosp Munich, Dr v Haunersches Childrens Hosp, Munich, Germany
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [11] Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates
    Dingli, D
    Gastineau, DA
    Gilchrist, GS
    Nichols, WL
    Wilke, JL
    HAEMOPHILIA, 2002, 8 (05) : 629 - 634
  • [12] Inhibitor development and efficacy of recombinant vs. plasma-derived factor VIII concentrates in haemophilia A patients
    Siegmund, B.
    Richter, H.
    Pollmann, H.
    Orlovic, M.
    Gottstein, S. .
    Klamroth, R.
    HAEMOPHILIA, 2008, 14 : 51 - 51
  • [13] Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates
    Scharrer, I
    Bray, GL
    Neutzling, O
    HAEMOPHILIA, 1999, 5 (03) : 145 - 154
  • [14] Beriate® P in the treatment of patients with haemophilia A: update of a long-term pharmacovigilance
    Klamroth, R.
    Heller, C.
    Holzhauer, S.
    Juers, M.
    Kurnik, K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 664 - 664
  • [15] Lower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments
    Biron-Andreani, Christine
    Diaz, Isabelle
    Navarro, Robert
    Schved, Jean-Francois
    HEMATOLOGIE, 2019, 25 (02): : 93 - 99
  • [16] Interim data on long-term efficacy, safety and tolerability of a plasma-derived factor VIII concentrate in 109 patients with severe haemophilia A
    Nemes, L.
    Pollmann, H.
    Becker, T.
    HAEMOPHILIA, 2012, 18 (04) : 496 - 502
  • [17] Use of a plasma-derived high-purity and double viral inactivated factor VIII concentrate in the treatment of von Willebrand disease
    Villar, A
    Jimenez-Yuste, V
    Canales, M
    Morado, M
    Gago, J
    Sanjurjo, MJ
    Quintana, M
    Magallon, M
    Hernandez-Navarrro, F
    THROMBOSIS AND HAEMOSTASIS, 1999, : 796 - 796
  • [18] Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients
    Deitcher, SR
    Tuller, J
    Johnson, JA
    HAEMOPHILIA, 1999, 5 (02) : 88 - 95
  • [19] Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data
    Kouides, Peter
    Wawra-Hehenberger, Kathrin
    Sajan, Anna
    Mead, Henry
    Simon, Toby
    TRANSFUSION, 2017, 57 (10) : 2390 - 2403
  • [20] HIGH-PURITY FACTOR-VIII CONCENTRATES FOR THE TREATMENT OF HIV-POSITIVE PATIENTS WITH HEMOPHILIA
    SULTAN, Y
    BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 : S80 - S81
12345